Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

Inclusion Criteria: * •Patients over 18, under 70 years of age * The chronic alcohol intake patients * Current the heavy drinker over 3month, Day the average alcohol consumption Male\>=60g, Female\>=40mg y-GTP increase Male\>=75, Female\>=35 * Over 1.5 ratio of AST to ALT * Patients who have chronoc alcohol disease Exclusion Criteria: * Patients who have liver disease with the cause different with the alcohol except * Patients who have pyridoxine allergy or history * Patients who are judged by investigator that participation of the study is difficult due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor, serious metabolic disease, severe renal disease, severe pulmonary disease, severe cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease and etc * Patients taking other investigational product within 90 days prior to the participation in the study. * Patients who has been taken any medications that could affect the treatment : hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic acid, pentoxifylline, lont-term use of NSAIDs, statins, neuroleptics, anti convulsive medications, high-dose acetaminophen(\>=2.5g/day) * Patients who have received treatment that may affect liver function within 1 month prior to the participation in the study * Patient who considered ineligible for participation in the study as Investigator's judgment